Blueprint Medicines Corp BPMC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BPMC is a good fit for your portfolio.
News
-
Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
-
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting
-
Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Blueprint Medicines to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024
Trading Information
- Previous Close Price
- $90.73
- Day Range
- $90.47–94.98
- 52-Week Range
- $43.89–101.00
- Bid/Ask
- $88.22 / $96.64
- Market Cap
- $5.69 Bil
- Volume/Avg
- 725,963 / 814,109
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 22.58
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 655
Comparables
Valuation
|
Metric
|
BPMC
|
VRDN
|
VTYX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 43.54 | 2.95 | 1.03 |
Price/Sales | 22.58 | 1,835.80 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
BPMC
VRDN
VTYX
Financial Strength
|
Metric
|
BPMC
|
VRDN
|
VTYX
|
|---|---|---|---|
Quick Ratio | 3.51 | 17.93 | 11.33 |
Current Ratio | 3.76 | 18.26 | 11.87 |
Interest Coverage | −25.93 | −137.76 | — |
Quick Ratio
BPMC
VRDN
VTYX
Profitability
|
Metric
|
BPMC
|
VRDN
|
VTYX
|
|---|---|---|---|
Return on Assets (Normalized) | −37.19% | −42.76% | −48.02% |
Return on Equity (Normalized) | −137.85% | −82.42% | −51.90% |
Return on Invested Capital (Normalized) | −70.74% | −50.70% | −55.64% |
Return on Assets
BPMC
VRDN
VTYX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ssqzcqcbzd | Byyxq | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xkvfdpzp | Xnxmbqz | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Xcvyktpsc | Tsjhhm | $97.8 Bil | |
MRNA
| Moderna Inc | Hqcwnsfxd | Jbnj | $41.3 Bil | |
ARGX
| argenx SE ADR | Xlrcgkbv | Mstg | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Jmbrtqkmx | Tnnjx | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Pntmtvssw | Dtnrvj | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Khvnfyh | Chycf | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Bqxqyjpjk | Txksd | $12.5 Bil | |
INCY
| Incyte Corp | Jcrtckjm | Fwypcl | $11.6 Bil |